---
document_datetime: 2023-09-21 20:44:42
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zoledronic-acid-hospira-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: zoledronic-acid-hospira-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.6290544
conversion_datetime: 2025-12-28 02:57:08.300398
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zoledronic acid Hospira

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|----------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| N/0045               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   | 01/10/2021                          |                                             | PL                               |                                   |
| PSUSA/3149/ 202008   | Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures) | 09/04/2021                          | n/a                                         |                                  | PRAC Recommendation - maintenance |
| IA/0044              | A.7 - Administrative change - Deletion of                                                          | 12/02/2021                          |                                             | Annex II and                     |                                   |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            | PL          |                      |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------|
| IB/0042/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 28/09/2020 | 22/10/2020 | SmPC and PL | the MAH              |
| IA/0041/G | This was an application for a group of variations. change - Change in the name                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 27/08/2020 | n/a        |             | A.4 - Administrative |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                    | and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or   |            |            |    |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| PSUSA/3149/ 201908 | Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/04/2020 | n/a        |    | PRAC Recommendation - maintenance |
| N/0039             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 02/12/2019 | 12/02/2020 | PL |                                   |
| IA/0038            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 16/05/2019 | n/a        |    |                                   |
| PSUSA/3149/ 201808 | Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/04/2019 | n/a        |    | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| N/0037             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                       | 09/04/2019   | 12/02/2020   | PL                     |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------|
| IA/0036            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                          | 05/02/2019   | 12/02/2020   | Annex II and PL        |                                   |
| N/0034             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                       | 24/10/2018   | 12/02/2020   | PL                     |                                   |
| T/0033             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                    | 06/08/2018   | 20/09/2018   | SmPC, Labelling and PL |                                   |
| PSUSA/3149/ 201708 | Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)                                                                                                                                                                                                                                                                                                                                                     | 12/04/2018   | n/a          |                        | PRAC Recommendation - maintenance |
| IB/0032            | B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products                                                                                                                                                                                                                                                                                                                              | 21/03/2018   | n/a          |                        |                                   |
| IAIN/0031/G        | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - | 12/02/2018   | 20/09/2018   | Annex II and PL        |                                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0030          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                             | 07/12/2017   | 20/09/2018   | Annex II and PL                  |                                                                                                                                                                                                                                                                                       |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0028             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 13/11/2017   | 20/09/2018   | PL                               |                                                                                                                                                                                                                                                                                       |
| R/0026             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 22/06/2017   | 24/08/2017   | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Zoledronic acid Hospira in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0027/G          | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol | 10/08/2017   | n/a          |                                  |                                                                                                                                                                                                                                                                                       |
| PSUSA/3149/ 201608 | Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 21/04/2017   | 16/06/2017   | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                   |            |            |                        | PSUSA/3149/201608.   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------|
| N/0025      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                  | 16/02/2017 | 16/06/2017 | Labelling and PL       |                      |
| IB/0023     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                      | 19/08/2016 | 16/06/2017 | SmPC and PL            |                      |
| N/0022      | Update of the package leaflet with revised contact details of the local representatives for Belgium, Germany, Spain, Ireland, Luxembourg, the Netherlands, Austria and Portugal. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 17/06/2016 | 16/06/2017 | PL                     |                      |
| IG/0693     | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                | 02/06/2016 | n/a        |                        |                      |
| IG/0645     | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                   | 17/12/2015 | n/a        |                        |                      |
| IAIN/0019/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name                                                                                                                                                                               | 10/12/2015 | 24/06/2016 | SmPC, Labelling and PL |                      |

<div style=\"page-break-after: always\"></div>

|         | and/or address of the MAH C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                                                         |            |            |                       |           |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------|
| IB/0018 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by                                                                                                                                                                                                                                                                                                                         | 27/10/2015 | 24/06/2016 | Annex II              | the MAH   |
|         | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 01/07/2015 | 24/06/2016 | SmPC, Annex II and PL | IB/0017/G |
| IG/0555 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the                                                                                                                                                                                                                                                                                                                                                                                                                            | 22/05/2015 | n/a        |                       |           |

<div style=\"page-break-after: always\"></div>

|           | PSMF location                                                                                                                                                                                                                                                                                                         |            |            |             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IB/0015   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                          | 19/12/2014 | 11/02/2015 | SmPC and PL |
| IB/0014/G | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 12/12/2014 | n/a        |             |
| IG/0477   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                       | 03/09/2014 | n/a        |             |
| IB/0012   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                          | 25/07/2014 | 11/02/2015 | SmPC        |

<div style=\"page-break-after: always\"></div>

| PSUSA/3149/ 201308   | Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)                                                                                                                                                                                                                                                                                                      | 10/04/2014   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0010              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                            | 01/04/2014   | 11/02/2015 | SmPC and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IG/0382              | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                         | 02/12/2013   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0008/G            | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.6.b - Change(s) to therapeutic indication(s) - Deletion of a therapeutic indication | 21/11/2013   | 31/01/2014 | SmPC, Annex II and PL | Update of SmPC section 4.4 Special warnings and precautions for 5mg/100 ml strength as requested by the CHMP further to assessment of Aclasta PSUR 9 to include observation of acute renal failure after a single administration, and to advise calculation of creatinine clearance based upon actual body weight using the Cockroft -Gault formula prior to each dose. Deletion of reference to osteoporosis indication in SmPC section 4.1, 4.2 and 5.1 and PL sections 1 and 3 due to the patent situation and as per legal advice. Accordingly update of physician educational material, also reflecting increased risk in subjects of advanced age. |
| IAIN/0007            | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                      | 03/09/2013   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IG/0317   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                 | 23/07/2013   | n/a        |                       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|
| IB/0004   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 16/07/2013   | 31/01/2014 | SmPC, Annex II and PL |
| IAIN/0006 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                             | 12/07/2013   | n/a        |                       |
| IAIN/0003 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                             | 13/05/2013   | n/a        |                       |
| IB/0001   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                      | 19/04/2013   | 31/01/2014 | SmPC                  |
| IG/0286   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                 | 12/04/2013   | n/a        |                       |